Application of Engineered Dendritic Cell Vaccines in Cancer Immunotherapy: Challenges and Opportunities
Authors:
- 14 November 2023
- journal article
- review article
- Published by Springer Nature in Current Treatment Options in Oncology
- Vol. 24 (12) , 1703-1719
Abstract
Opinion statement The primary objective of this study is to evaluate the effectiveness of cancer vaccines containing genetically modified dendritic cells (DCs) in inducing transformational immune responses. This paper sheds considerable light on DCs’ function in advancing treatment techniques. This objective is achieved by thoroughly analyzing the many facets of DCs and their strategic integration into cancer treatment. Due to their role as immune response regulators, DCs can potentially enhance cancer treatment strategies. DCs have the potential to revolutionize immunotherapy, as shown by a comprehensive analysis of their numerous characteristics. The review deftly transitions from examining the fundamentals of preclinical research to delving into the complexities of clinical implementation while acknowledging the inherent challenges in translating DC vaccine concepts into tangible progress. The analysis also emphasizes the potential synergistic outcomes that can be achieved by combining DC vaccines with established pharmaceuticals, thereby emphasizing the importance of employing a holistic approach to enhance treatment efficacy. Despite the existence of transformative opportunities, advancement is hindered by several obstacles. The exhaustive analysis of technical complexities, regulatory dynamics, and upcoming challenges provides valuable insights for overcoming obstacles requiring strategic navigation to incorporate DC vaccines successfully. This document provides a comprehensive analysis of the developments in DC-based immunotherapy, concentrating on its potential to transform cancer therapy radically.Keywords
This publication has 95 references indexed in Scilit:
- IL-12p70–producing patient DC vaccine elicits Tc1-polarized immunityJournal of Clinical Investigation, 2013
- Immune response, clinical outcome and safety of dendritic cell vaccine in combination with cytokine-induced killer cell therapy in cancer patientsOncology Letters, 2013
- Targeting CD4+ T-Helper Cells Improves the Induction of Antitumor Responses in Dendritic Cell–Based VaccinationCancer Research, 2013
- Cancer immunotherapy via dendritic cellsNature Reviews Cancer, 2012
- PD-1 Blockade by CT-011, Anti-PD-1 Antibody, Enhances Ex Vivo T-cell Responses to Autologous Dendritic Cell/Myeloma Fusion VaccineJournal of Immunotherapy, 2011
- Dendritic Cell Based Tumor Vaccination in Prostate and Renal Cell Cancer: A Systematic Review and Meta-AnalysisPLOS ONE, 2011
- Designing Vaccines Based on Biology of Human Dendritic Cell SubsetsImmunity, 2010
- Indoleamine 2,3-dioxygenase-expressing leukemic dendritic cells impair a leukemia-specific immune response by inducing potent T regulatory cellsHaematologica, 2010
- Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigensJournal of Experimental Medicine, 2010
- Suppressive Influences in the Immune Response to CancerJournal of Immunotherapy, 2009